Global
About
Development milestones Mission&Vision Founder Research Achievement
Technology Platforms
Single domain antibody Five core technology platforms
PIPELINE
BUSINESS PARTNERSHIPS
Product Out-Licensing Co-Development
investor
Career development
Our Story Social Recruitment
News
Company News Media
Contact Us
Company Address Online Message
×
Our Story

Share the latest information

Our Story
News
Company News
Media
2025-03-25
Novamab Announces Successful Completion of LQ036 Phase IIa Clinical Trial Demonstrating Superior Efficacy and Safety – The World’s First Inhaled IL-4Rα Biologic Offers an Innovative Treatment Option for Asthma Patients
More
2022-08-22
Celebrate the official commencement of GMP production!
More
2022-07-15
Novamab participated in the development of COVID-19 neutralizing antibody molecular imaging technology, and the research results were published in Research!
More
2022-05-07
The research achievements on COVID-19 by Novamab and Professor Li Henan of Jiangsu University were published in the international journal Analytica Chimica Acta!
More
2022-01-27
The clinical trial of LQ036, the world's first inhaled nanoantibody drug for the treatment of moderate and severe asthma, was approved by CDE!
More
2021-12-31
Dr. Wan Yakun, founder of Novamab, was successfully selected as "Zhangjiang Outstanding Talent in 2021"!
More
2021-11-29
Novamab announced that its LQ036 (recombinant anti-IL-4Ra single-domain antibody aerosol) was accepted by IND!
More
2021-10-18
The fourth anniversary celebration of Novamab was successfully held!
More
2021-10-11
Novamab announced that its anti-IL-4R sdAb LQ036 clinical phase I study completed the first subject administration!
More
2021-06-29
Novamab has been recognized as a pilot patent enterprise in Shanghai!
More
2021-04-08
Novamab has obtained tens of millions of A+rounds of financing!
More
Total 51 123456